Search

Zentalis Pharmaceuticals Inc

Fermé

2.88 -5.88

Résumé

Variation du prix de l'action

24h

Actuel

Min

3

Max

3.13

Chiffres clés

By Trading Economics

Revenu

-42M

-78M

BPA

-0.59

Employés

106

EBITDA

-42M

-77M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+190.43% upside

Dividendes

By Acuity

Prochains Résultats

6 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-44M

287M

Ouverture précédente

8.76

Clôture précédente

2.88

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 sept. 2026, 23:56 UTC

Correlated Moves

TE Connectivity PLC declined slightly in after-market trading, amid concerns over economic momentum following a drop in the Richmond Fed Manufacturing Index.

22 sept. 2026, 23:56 UTC

Raymond James Financial Inc is trading modestly lower in after-market hours, continuing a decline since Tuesday and remaining near the low end of its one-month range.

22 sept. 2026, 23:56 UTC

Correlated Moves

Hess Midstream LP is trading lower in after-market hours, following a flat session and amid a decline in shares of Targa Resources Corp.

22 sept. 2026, 23:56 UTC

Correlated Moves

Agree Realty Corp is trading slightly higher in after-market hours, influenced by positive earnings reports from consumer discretionary companies.

22 sept. 2026, 23:56 UTC

Plumas Bancorp remains roughly flat in after-market trading, showing little change since Tuesday's close and oscillating around the midpoint of its one-month trading range.

22 sept. 2026, 23:56 UTC

Correlated Moves

Delek US Holdings Inc is trading lower in after-market hours, potentially in sympathy with HF Sinclair Corp, which has also declined.

22 sept. 2026, 23:55 UTC

Andersons Inc is experiencing notable gains in after-market trading, recovering from previous lower closes but remains below its 20-day moving average.

22 sept. 2026, 23:55 UTC

Pentair PLC is trading modestly higher in after-market hours, continuing a gradual increase, though it remains below its 20-day moving average.

22 sept. 2026, 23:55 UTC

Healthequity Inc. is trading modestly lower in after-market hours, continuing a decline from Tuesday's close and remaining below its 20-day moving average.

22 sept. 2026, 23:55 UTC

M&T Bank Corp is trading modestly higher in after-market hours, remaining above its opening level despite a slight pullback during the regular session.

22 sept. 2026, 23:55 UTC

Darling Ingredients Inc is trading modestly lower in after-market hours, continuing a four-session decline and remaining significantly below its 20-day moving average.

22 sept. 2026, 23:55 UTC

News

Roivant Sciences Ltd is higher in after-market trading following positive Phase 2 trial results for mosliciguat, showing significant improvements in pulmonary hypertension patients.

22 sept. 2026, 23:52 UTC

CarMax Inc. is trading modestly lower in after-market hours, continuing a decline since Tuesday's close and remaining below its 20-day moving average.

22 sept. 2026, 23:51 UTC

News

Itron Inc's stock is declining in after-market trading, despite the launch of its Riva IEC Grid Edge Portfolio in the Asia Pacific region.

22 sept. 2026, 23:51 UTC

MACOM Technology Solutions Holdings Inc is up in after-market trading, continuing a trend of seven consecutive higher daily closes and remaining above its 20-day moving average.

22 sept. 2026, 23:51 UTC

Old Dominion Freight Line Inc is trading modestly lower in after-market hours, remaining significantly below its 20-day moving average after a brief rise earlier.

22 sept. 2026, 23:51 UTC

First Solar Inc is trading modestly lower in after-market hours, following a notable dip earlier in the session and remaining below its 20-day moving average.

22 sept. 2026, 23:51 UTC

Eversource Energy is trading modestly higher in after-market hours, despite recent lower performance and positioning below its 20-day moving average.

22 sept. 2026, 23:51 UTC

Nucor Corp is trading modestly lower in after-market hours, continuing a downward trend since Tuesday's close and positioned below its 20-day moving average.

22 sept. 2026, 23:51 UTC

Targa Resources Corp is seeing a modest decline in after-market trading, continuing a trend of three consecutive lower daily closes.

22 sept. 2026, 23:51 UTC

Correlated Moves

SM Energy Co is trading modestly lower in after-market hours, continuing a decline amid concerns from the Richmond Fed Manufacturing Index's unexpected fall.

22 sept. 2026, 23:51 UTC

Brazil's Unemployment Rate Set to Release on September 29, Expected to Reflect Continued Labor Market Improvement Amid Global Economic Concerns.

22 sept. 2026, 23:51 UTC

Australia's S&P Global Services PMI at 51.4 signals slight expansion, but mixed retail forecasts raise concerns about consumer spending ahead of the holiday season.

22 sept. 2026, 23:51 UTC

Australia's S&P Global Manufacturing PMI Flash at 49.3 Signals Contraction, Raising Concerns Over Economic Growth and Potential Monetary Policy Adjustments.

22 sept. 2026, 23:51 UTC

Japan's Industrial Production Report Set for Release on September 29, Amidst Positive Trends and Global Economic Influences.

22 sept. 2026, 23:51 UTC

Japan's Retail Sales Data Release on September 29 Faces Caution Amid Interest Rate Hike and Yen Weakness.

22 sept. 2026, 23:50 UTC

News

Coeur Mining plans a record $158 million exploration investment for 2026, more than double 2025's budget, as shares rise in after-market trading.

22 sept. 2026, 23:50 UTC

Cinemark Holdings Inc is declining in after-market trading, falling from earlier gains and nearing the lower end of its one-month trading range.

22 sept. 2026, 23:50 UTC

Veeva Systems Inc is trading modestly higher in after-hours action, remaining below its 20-day moving average and around the midpoint of its one-month range.

22 sept. 2026, 23:50 UTC

Aspen Aerogels Inc is trading lower in after-market hours, showing a significant decline from Tuesday's close, though still above its 20-day moving average.

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

190.43% hausse

Prévisions sur 12 Mois

Moyen 8.8 USD  190.43%

Haut 11 USD

Bas 5 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

5

Achat

1

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.